化工社化工社 化学情報印刷レポート · 研究参考用
クロチアゼパム
リリフター · ロミニアン · ニラタック · 5-(2-クロロフェニル)-7-エチル-1-メチル-1,3-ジヒドロ-2H-チエノ[2,3-e]-1,4-ジアゼピン-2-オン · リルミン · クロチアゼパム · リーゼ · 5-(o-クロロフェニル)-7-エチル-1,3-ジヒドロ-1-メチル-2H-チエノ[2,3-e]-1,4-ジアゼピン-2-オン
識別子と物理属性
| CAS No. | 33671-46-4 |
|---|---|
| 分子式 | C16H15ClN2OS |
| 平均分子量 | 318.8 g/mol |
| 単同位体質量 | 318.059362 g/mol |
| SMILES | CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl |
| InChIKey | CHBRHODLKOZEPZ-UHFFFAOYSA-N |
| PubChem CID | 2811 |
| ChEMBL | CHEMBL1697737 |
| ChEBI | CHEBI:31425 |
| EC No. | 251-627-3 |
| DTXSID | DTXSID0022852 |
| 現地名 | クロチアゼパム |
化学・物理的性質
| XLogP | 3.5 |
|---|---|
| 極性表面積 | 60.9 |
| 水素結合供与体数 | 0 |
| 水素結合受容体数 | 3 |
| 回転可能結合数 | 2 |
| 重原子数 | 21 |
| 形式電荷 | 0 |
| 複雑度 | 442 |
| 医薬品 | DEA NFLIS-Drug Category -> BenzodiazepinesDEA Schedule IV Controlled Substance -> DepressantsPharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds |
| LogP（分配係数） | 3.183.35 |
| 溶解度 | 5.37e-03 g/LDMF: 15 mg/mlDMSO: 15 mg/mlDMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml |
| Human Drugs | Breast FeedingLactationMilk, HumanHypnotics and SedativesAnti-Anxiety AgentsBenzodiazepinesPharmaceuticals |
| 融点 | 105-106118 - 120 °C105-106° |
| Physical Description | Solid |
| 沸点 | 523.7±50.0 °C(Predicted) |
| 密度 | 1.1625 (rough estimate) |
| 屈折率 | 1.6100 (estimate) |
| 外観・状態 | A crystalline solid |
| pKa（酸解離定数） | 2.36±0.20(Predicted) |
化学的特性
Off-White Solid
安全性と法規制
| GHS 分類 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P261, P263, P264, P270, P271, P280, P301+P317, P304+P340, P318, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 規制情報 | DEA schedule IV controlled substance |
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
| Treatment | General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended. |
| 健康影響 | They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease. |
| 暴露経路 | Oral |
| 毒性の概要 | Clotiazepam acts at the benzodiazepine receptors (BZD). This agonizes the action of GABA, increasing the frequency of opening of the channel chlorinates and penetration of the ions chlorinates through the ionophore. Increase in membrane polarization decreases the probability of discharge of neurons. |
用途
用途
薬理・生理作用研究用。
用途
ベンゾジアゼピン系化合物で す。GABA受容体に作用し、中枢神経抑制作 用を示します。作用時間は、短時間型とされ ています。
用途
ベンゾジアゼピン系化合物で す。GABA 受容体に作用し、中枢神経抑制作 用を示します。作用時間は、短時間型とされ ています。
使用
A thienodiazepine derivative that possesses anxiolytic, skeletal muscle relaxant anticonvulsant, sedative properties as well as contributing to siginificant increase stage 2 NREM sleep. It binds to be nzodiazepine site of the GABAA receptor where it acts as a full agonist resulting in enhanced GABA inhibitory effect at the GABAA receptor. Controlled Substance.